A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Overview

This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas.

Full Title of Study: “A Phase I Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Sequential Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 15, 2024

Detailed Description

This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas. Dose Escalation Phase: Approximately 40-50 subjects with a maximum number of 62; 1-20 subjects for enhanced PDx cohort. Dose Expansion Phase: Estimated between 2 and 5 cohorts, each of approximately 40-50 patients to be expanded.

Interventions

  • Drug: ATG-101
    • ATG-101 will be administered intravenously once every 28 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial. The Dose Expansion Phase will begin at the defined MTD, RP2D, or biologically optimal dose.

Arms, Groups and Cohorts

  • Experimental: ATG-101
    • Dose Escalation Phase: Will be conducted with an enhanced PDx cohort. Dose Expansion Phase: Subjects with advanced or metastatic solid tumors and mature B-NHLs will be enrolled.

Clinical Trial Outcome Measures

Primary Measures

  • AEs/SAEs
    • Time Frame: One year after last patient first dose
    • Toxicity will be graded according to the NCI CTCAE, Version 5.0.
  • DLT (for Dose Escalation Phase only)
    • Time Frame: One year after last patient first dose
    • The DLTs will be evaluated during Cycle 1 of treatment. Toxicity will be graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events. The DLTs for this study may include the following: Cytokine release syndrome, Hematologic toxicity, Non-hematologic toxicity.

Secondary Measures

  • ORR
    • Time Frame: One year after last patient first dose
    • To evaluate preliminary anti tumor activity of ATG-101
  • DCR
    • Time Frame: One year after last patient first dose
    • To evaluate preliminary anti tumor activity of ATG-101
  • PFS
    • Time Frame: One year after last patient first dose
    • To evaluate preliminary anti tumor activity of ATG-101
  • OS
    • Time Frame: One year after last patient first dose
    • To evaluate preliminary anti tumor activity of ATG-101
  • The incidence of ADA and NAb
    • Time Frame: One year after last patient first dose
    • To evaluate the immunogenicity of ATG-101
  • Peak Plasma Concentration (Cmax)
    • Time Frame: One year after last patient first dose
    • To evaluate the maximum plasma concentration (Cmax) of ATG-101 in Chinese patient population
  • Peak Plasma Concentration(Tmax)
    • Time Frame: One year after last patient first dose
    • To evaluate the time to reach Tmax of ATG-101 in Chinese patient population

Participating in This Clinical Trial

Inclusion Criteria

1. Provision of signed and dated, written informed consent prior to any study-specific procedures, sampling, and analyses. 2. Aged 18 to 75 years as of the date of consent. 3. Histological or cytological confirmation of a solid tumor, and has relapsed or refractory from standard therapies. 4. Subjects with solid tumors have at least 1 measurable lesion per RECIST v1.1. 5. Estimated life expectancy of a minimum of 12 weeks. 6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at ICF signature. Exclusion Criteria:

1. Subjects with CNS tumors or known CNS metastases will be excluded from the Dose Escalation Phase. 2. Prior treatment with a 4-1BB agonist. 3. Subjects with primary liver cancer. 4. Known history of human immunodeficiency virus infection. 5. History of hypersensitivity or history of allergic reactions attributed to drugs with a similar chemical or biologic structure or class to ATG-101. 6. Pregnant or nursing females.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Antengene (Hangzhou) Biologics Co., Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Yiqiang Zhao, MD, Study Director, Medical Director
  • Overall Contact(s)
    • Sara Wang, 17601350610, sara.wang@antengene.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.